Regions Financial Corp’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $348K | Sell |
2,066
-615
| -23% | -$91.2K | ﹤0.01% | 700 |
|
|
2026
Q1 | $353K | Sell |
2,681
-146
| -5% | -$19.4K | ﹤0.01% | 699 |
|
|
2025
Q4 | $401K | Buy |
2,827
+238
| +9% | +$34.5K | ﹤0.01% | 659 |
|
|
2025
Q3 | $363K | Buy |
2,589
+6
| +0.2% | +$813 | ﹤0.01% | 685 |
|
|
2025
Q2 | $325K | Sell |
2,583
-106
| -4% | -$12.2K | ﹤0.01% | 693 |
|
|
2025
Q1 | $297K | Buy |
2,689
+100
| +4% | +$12.7K | ﹤0.01% | 691 |
|
|
2024
Q4 | $353K | Sell |
2,589
-35
| -1% | -$4.33K | ﹤0.01% | 651 |
|
|
2024
Q3 | $302K | Sell |
2,624
-543
| -17% | -$74.4K | ﹤0.01% | 703 |
|
|
2024
Q2 | $436K | Sell |
3,167
-18
| -0.6% | -$2.47K | ﹤0.01% | 600 |
|
|
2024
Q1 | $439K | Sell |
3,185
-155
| -5% | -$21.2K | ﹤0.01% | 617 |
|
|
2023
Q4 | $440K | Sell |
3,340
-125
| -4% | -$14.4K | ﹤0.01% | 614 |
|
|
2023
Q3 | $390K | Sell |
3,465
-120
| -3% | -$12.6K | ﹤0.01% | 606 |
|
|
2023
Q2 | $338K | Sell |
3,585
-69
| -2% | -$6.74K | ﹤0.01% | 669 |
|
|
2023
Q1 | $370K | Sell |
3,654
-215
| -6% | -$22.4K | ﹤0.01% | 658 |
|
|
2022
Q4 | $462K | Sell |
3,869
-50
| -1% | -$5.86K | ﹤0.01% | 602 |
|
|
2022
Q3 | $416K | Sell |
3,919
-168
| -4% | -$17K | ﹤0.01% | 609 |
|
|
2022
Q2 | $398K | Buy |
4,087
+484
| +13% | +$44.7K | ﹤0.01% | 643 |
|
|
2022
Q1 | $338K | Buy |
3,603
+877
| +32% | +$74.3K | ﹤0.01% | 725 |
|
|
2021
Q4 | $232K | Sell |
2,726
-434
| -14% | -$39.9K | ﹤0.01% | 846 |
|
|
2021
Q3 | $303K | Buy |
3,160
+70
| +2% | +$6.61K | ﹤0.01% | 760 |
|
|
2021
Q2 | $301K | Sell |
3,090
-1,412
| -31% | -$135K | ﹤0.01% | 752 |
|
|
2021
Q1 | $437K | Buy |
4,502
+63
| +1% | +$6.61K | ﹤0.01% | 608 |
|
|
2020
Q4 | $425K | Sell |
4,439
-18
| -0.4% | -$1.74K | ﹤0.01% | 595 |
|
|
2020
Q3 | $429K | Buy |
4,457
+1
| +0% | +$116 | ﹤0.01% | 558 |
|
|
2020
Q2 | $544K | Buy |
4,456
+1,055
| +31% | +$117K | 0.01% | 511 |
|
|
2020
Q1 | $295K | Buy |
3,401
+307
| +10% | +$30K | ﹤0.01% | 592 |
|
|
2019
Q4 | $333K | Buy |
3,094
+60
| +2% | +$6.28K | ﹤0.01% | 644 |
|
|
2019
Q3 | $273K | Sell |
3,034
-33
| -1% | -$3.08K | ﹤0.01% | 675 |
|
|
2019
Q2 | $259K | Buy |
3,067
+90
| +3% | +$7.39K | ﹤0.01% | 705 |
|
|
2019
Q1 | $262K | Buy |
2,977
+688
| +30% | +$57.5K | ﹤0.01% | 706 |
|
|
2018
Q4 | $164K | Buy |
2,289
+1,005
| +78% | +$96.3K | ﹤0.01% | 821 |
|
|
2018
Q3 | $158K | Sell |
1,284
-10
| -0.8% | -$1.14K | ﹤0.01% | 894 |
|
|
2018
Q2 | $127K | Buy |
+1,294
| New | +$116K | ﹤0.01% | 952 |
|
Other funds holding NBIX
Regions Financial Corp's NBIX Position: Q2 2026 in Review
Regions Financial Corp reduced its Neurocrine Biosciences (NBIX) stake by 23% in Q2 2026, selling an estimated $91.2K and leaving 2,066 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #700.
Regions Financial Corp first reported a position in NBIX in Q2 2018 and has held it in 33 quarters since. The position peaked at $544K in Q2 2020. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Regions Financial Corp held 2,066 shares of Neurocrine Biosciences worth $348K as of Q2 2026.
- Regions Financial Corp sold 615 Neurocrine Biosciences shares in Q2 2026, an estimated $91.2K.
- Neurocrine Biosciences made up ﹤0.01% of Regions Financial Corp's portfolio in Q2 2026, its #700 holding.
- Regions Financial Corp first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 33 quarters since.
- Regions Financial Corp's Neurocrine Biosciences position peaked at $544K in Q2 2020.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Regions Financial Corp's 13F filing for Q2 2026, filed 10 Aug 2026.